Respinova

Company Overview

Snapshot

Founded in September 2008 by Yuval Avni, Respinova operated with 1–10 employees and raised $7.76 million across four funding rounds. The company received FDA 510(k) clearance for its PulseHaler device in April 2021, a significant milestone for its respiratory disease treatment technology. However, Respinova ceased operations in March 2025.

Business overview

Respinova developed the PulseHaler, a noninvasive technology designed to treat the core pathophysiology of chronic obstructive pulmonary disorder (COPD). This proprietary multi-frequency air pressure pulse technology aims to improve lung function, exercise capacity, and quality of life for COPD patients across all severity stages. The company's technology also demonstrated the ability to deliver drugs more effectively to the lung periphery, positioning it within the medical devices, medical treatment, and therapeutics sectors, serving patients and providers in the healthcare market.

Strategic signal

Respinova ceased operations in March 2025, indicating a complete halt to its business activities. This closure signals to investors and innovation teams that the company's efforts to commercialize its PulseHaler technology for COPD treatment have concluded, despite earlier regulatory approvals and clinical validations.

Company Intelligence Q&A

What is the primary product developed by Respinova?

Respinova developed the PulseHaler, a noninvasive medical device designed to treat chronic obstructive pulmonary disorder (COPD) by using proprietary multi-frequency air pressure pulse technology.

When did Respinova cease operations?

Respinova ceased to operate in March 2025.

What significant regulatory milestone did Respinova achieve?

In April 2021, Respinova was granted FDA 510(k) clearance for its PulseHaler device, allowing it to market the innovative technology for respiratory diseases.

What was the total capital raised by Respinova?

Respinova raised a total of $7.76 million across four funding rounds.

Did Respinova receive support from the European Union?

Yes, Respinova received funding from the European Union's Horizon 2020 program in February 2019 and December 2017, supporting the development and commercialization of its PulseHaler solution.